Saltar al contenido
Merck

1368609

USP

Lisinopril

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

300 MG
MXP 9,751.00

MXP 9,751.00


Check Cart for Availability

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
300 MG
MXP 9,751.00

About This Item

Fórmula empírica (notación de Hill):
C21H31O5N3 · 2H2O
Número de CAS:
Peso molecular:
441.52
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

MXP 9,751.00


Check Cart for Availability

Solicitar un pedido a granel

grado

pharmaceutical primary standard

familia API

lisinopril

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

Clave InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Información sobre el gen

human ... ACE(1636)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Lisinopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Lisinopril and Hydrochlorothiazide Tablets
  • Lisinopril Compounded Oral Suspension
  • Lisinopril Tablets

Acciones bioquímicas o fisiológicas

Angiotensin converting enzyme (ACE) inhibitor.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Repr. 1A - STOT RE 2

Órganos de actuación

Kidney

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Stephen J Bright et al.
Australasian journal on ageing, 34(1), 33-37 (2013-10-15)
The Alcohol-Related Problems Survey (ARPS) reliably classifies drinking as non-hazardous, hazardous or harmful using scoring algorithms that consider quantity and frequency of alcohol use alone and in combination with health conditions, medication-use and functional status. Because it has been developed
Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.
M F Abdelmalek et al.
Digestive diseases and sciences, 42(4), 847-850 (1997-04-01)
K Simpson et al.
Drugs, 59(5), 1149-1167 (2000-06-14)
The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24
T D Giles
Zeitschrift fur Kardiologie, 80 Suppl 2, 35-39 (1991-01-01)
Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF. An improved effect on LV function and signs
C Valenzuela et al.
General pharmacology, 25(5), 825-832 (1994-09-01)
1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico